LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Anika Therapeutics Extends Availability of Integrity Implant System MT
Anika Therapeutics, Inc. Announces Full Market Release of the Integrity Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell 3000 Growth Index CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell Microcap Growth Index CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell 2000 Growth Index CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell 2000 Growth-Defensive Index CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell 3000E Growth Index CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell 2500 Growth Index CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell Small Cap Comp Growth Index CI
Caligan Partners Enters into a Cooperation Agreement with Anika Therapeutics CI
Anika Therapeutics Approves $40 Million Share Repurchase Program MT
Anika Therapeutics, Inc. announces an Equity Buyback for $40 million worth of its shares. CI
Anika Therapeutics, Inc. Announces Board Changes CI
Anika Therapeutics, Inc. authorizes a Buyback Plan. CI
Transcript : Anika Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on April 13, 2023. CI
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 EPS $0.09 MT
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 Revenue $40.5M, vs. Street Est of $39.1M MT
Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Anika Therapeutics, Inc. Announces Management Changes, Effective June 3, 2024 CI
Anika Therapeutics, Inc. Announces CFO Changes CI
Anika Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Anika Therapeutics, Inc.'s Equity Buyback announced on April 13, 2023 has expired. CI
Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on April 13, 2023. CI
Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating MT
Chart Anika Therapeutics, Inc.
More charts
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
28.55 USD
Average target price
31 USD
Spread / Average Target
+8.58%
Consensus
  1. Stock Market
  2. Equities
  3. ANIK Stock
  4. News Anika Therapeutics, Inc.
  5. Anika Therapeutics Extends Availability of Integrity Implant System